» Articles » PMID: 19808963

Structural Basis for the Binding of the Anticancer Compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to Human Glutathione S-transferases

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Oct 8
PMID 19808963
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Glutathione S-transferases (GST) constitute a superfamily of enzymes with diversified functions including detoxification from xenobiotics. In many human cancers, Pi class GST (GSTP1-1) is overexpressed and contributes to multidrug resistance by conjugating chemotherapeutics. In addition, GSTP1-1 displays antiapoptotic activity by interacting with c-Jun NH(2)-terminal kinase, a key regulator of apoptosis. Therefore, GSTP1-1 is considered a promising target for pharmaceutical treatment. Recently, a potent inhibitor of GSTs, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), was identified and tested on several tumor cell lines demonstrating high antiproliferative activity. To establish the structural basis of NBDHEX activity, we determined the crystal structure of NBDHEX bound to either GSTP1-1 or GSTM2-2 (mu class). NBDHEX in both cases binds to the H-site but occupies different positions. Furthermore, the compound is covalently attached to the GSH sulfur in the GSTM2-2 crystal, forming a sigma-complex, although it is bound but not conjugated in the GSTP1-1 crystal. Several differences in the H-sites of the two isozymes determine the higher affinity of NBDHEX for GSTM2-2 with respect to GSTP1-1. One such difference is the presence of Ile(104) in GSTP1-1 close to the bound NBDHEX, whereas the corresponding position is occupied by an alanine in GSTM2-2. Mutation of Ile(104) into valine is a frequent GSTP1-1 polymorphism and we show here that the Ile(104)Val and Ile(104)Ala variants display a 4-fold higher affinity for the compound. Remarkably, the GSTP1-1/Ile(104)Ala structure in complex with NBDHEX shows a considerable shift of the compound inside the H-site. These data might be useful for the development of new anticancer compounds.

Citing Articles

Isozyme-specific inhibition of GSTP1-1: a crucial element in cancer-targeting drugs.

Al-Najjar B, Helal M, Saqallah F, Bandy B RSC Med Chem. 2025; .

PMID: 39917632 PMC: 11795191. DOI: 10.1039/d4md00872c.


Advances in reversible covalent kinase inhibitors.

Zhao Z, Bourne P Med Res Rev. 2024; 45(2):629-653.

PMID: 39287197 PMC: 11796325. DOI: 10.1002/med.22084.


Novel coumarin-6-sulfonamide-chalcone hybrids as glutathione transferase P1-1 inhibitors.

Sabt A, Kitsos S, Ebaid M, Furlan V, Pantiora P, Tsolka M PLoS One. 2024; 19(8):e0306124.

PMID: 39141629 PMC: 11324126. DOI: 10.1371/journal.pone.0306124.


Rapid discovery of a novel "green" and natural GST inhibitor for sensitizing hepatocellular carcinoma to Cisplatin by visual screening strategy.

Mao L, Qin Y, Fan J, Yang W, Li B, Cao L J Pharm Anal. 2024; 14(5):100923.

PMID: 38799232 PMC: 11127223. DOI: 10.1016/j.jpha.2023.12.013.


Determining site occupancy of acetaminophen covalent binding to target proteins in vitro.

Geib T, Lento C, Marensi V, Thulasingam M, Haeggstrom J, Olsson M Anal Sci Adv. 2024; 2(5-6):263-271.

PMID: 38716151 PMC: 10989598. DOI: 10.1002/ansa.202000182.